What is going on with Amarantus What AMBS owns a
Post# of 30028
(Total Views: 616)
Posted On: 02/05/2020 11:29:51 PM
What is going on with Amarantus
What AMBS owns and what those companies have.
Hempori, Inc., - CBD
2 stores fronts at present - looking to grow aggressively
AMBS 51% of the outstanding shares of Hempori, and was granted an option to acquire the remaining shares from the existing shareholders until December 31, 2020 for additional common stock of Amarantus, or of a successor entity in the event Amarantus is acquired prior to year-end 2020.
Hempori generated over $350,000 from its 2 storefronts in fiscal year 2019.
Emerald Organic Products - CBD and...
https://www.emerald-organic.com
Emerald Organic Products Hires Ex-Quest Nutrition Executive as Head of Sales
Director of Worldwide Sales at Quest Nutrition
The Simply Good Foods Company (NASDAQ:SMPL) announced that it would acquire Quest Nutrition, LLC for $1 billion USD in cash on expected annual revenue of $345 million.
Pura Vida Vitamins
https://www.puravidavitamins.com/cbd-gummies/
PETV - PetVivo Holdings, Inc.
EMOR entered into an exclusive licensing agreement for the use of OraPatch™, a patented oral delivery method for various substances including caffeine and cannabidiol (“CBD”) from PetVivo Holdings, Inc.
The patented oral adhesion technology, OraPatch™, is a slowly degradable protein wafer-disc that attaches to and assimilates with the mouth’s inner lining. PetVivo is the holder of patents for this unique and cutting-edge method for nutraceutical and supplement delivery.
https://www.emerald-organic.com/press-release...ldings-inc
EMOR 51% stake in Bezalel’s Jewelry, Inc.
vending machine manufacturing and distributing company,
1. These unique vending machines employ facial recognition software and can positively identify people with I.D. from 143 countries worldwide.
“we are particularly excited about the machines presentation, which allows for HD quality advertising offering a significant revenue opportunity”
https://patents.justia.com/assignee/bezalel-s-jewelry-inc
Contract with
https://www.sportandwellnessltd.com
VPs
Wellness Executive VP Sales and Marketing, Chris Mattina
Patrick Kenny, CEO of Sport and Wellness Living.
https://www.traub.io/team/pat-kenny/
Amarantus is receiving an up-front payment of preferred stock in Emerald to be valued at a minimum of $66.6 million (the “Preferred”), and will receive single digit royalties, with a right to buy into up to double-digit royalties until April 2022. The Preferred is convertible into 33,333,333 shares of Emerald common stock in April 2022. Prior to April 2022, Amarantus may convert the Preferred stock to common stock in Emerald upon the common stock trading above $5 on average volume of 1,000,000 shares traded for a period of 20 days
Cutanogen / ESS owns 90.1%
MANF Therapeutics 100%
PhenoGuard
"We now intend to focus on developing these assets through strategic partnerships to unlock their full potential."
TBD - negotiations on-going eith EMOR
Elto Pharma AMBS’ 50.1%-owned
JV partner Psychogenics, Inc.
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease
Patent extends patent coverage for eltoprazine to 2034
The potential for cannabinoid pharmaceuticals is rooted in their potentially synergistic effects with other traditional pharmaceutical compounds, such as eltoprazine. We are very pleased with this first notice of allowance that we’ve received from this international patent family, and we expect to receive many more in the months from jurisdictions around the world, including the United States.”
1st Lab AMBS has direct access to
Todos Medical option to acquire Provista Dx
Provista Diagnostics, Inc., an in vitro diagnostics company with a CLIA/CAP certified lab
Provista Diagnostics has received investments of over $50M which it has used to develop a stable, antibody-based simple blood test that measures the presence of Tumor-associated Auto-Antibodies (TAAbs) and Serum Protein Biomarkers (SRPs)
Todos has exercised its exclusive option to acquire Amarantus’ remaining ownership in Breakthrough in exchange for approximately 49% ownership of Todos.
The transaction is expected to close in the frist half of 2020.
Videssa Breast DX CLIA certified
From the TBIA Platform
TM- B1 - CE Mark granted
TM-B2 - CE Mark granted
In parallel, Todos’ TM-B1 and TM-B2 assays will gain valuable information by piggybacking on Videssa’s patient flow
Also has TM-C1 Colon Cancer CE Mark granted
Orot+ will be responsible for marketing and distribution costs and execution associated with commercializing the breast cancer tests in Romania and Austria. Todos Medical will be able to use the data gathered from these initiatives to support further development and commercialization in other jurisdictions.
We look forward to working with Todos for many years to come
Todos and Orot are currently enrolling patients in a commercial validation study to support the commercial launch of the TM-B1 and TM-B2 blood tests later this year.
Orot+ has agreed to spend a minimum of $2.5M towards clinical development, regulatory approval and commercial launch of the tests by way of a soon to be formed Japanese Distribution Company
Todos & AMBS are working to complete the all-stock acquisition of Amarantus’ subsidiary Breakthrough Diagnostics into Todos Medical in the near future.
Breakthrough Diagnostics - 80.01%-owned by AMBS
LymPro Test ®
MSPrecise™
NuroPro.
Gerald was appointed as CEO of Todos primarily to help Todos implement its plans to bring its blood testing technologies into the US market and list its common stock onto a US national stock exchange, which would ultimately create substantial value for Amarantus
2nd Lab AMBS has access to
Avant Diagnostics, Inc, approx 30% of common
a tumor analysis company developing Theralink®,
Our laboratory is ~95% complete and we have one of our new Ph.D.’s, from George Mason University (“GMU”), on site busily preparing us for our lab opening
I may have missed something, just shows how much Gerald is doing and why Amarantus of new is not Amarantus of past.
Aloha
What AMBS owns and what those companies have.
Hempori, Inc., - CBD
2 stores fronts at present - looking to grow aggressively
AMBS 51% of the outstanding shares of Hempori, and was granted an option to acquire the remaining shares from the existing shareholders until December 31, 2020 for additional common stock of Amarantus, or of a successor entity in the event Amarantus is acquired prior to year-end 2020.
Hempori generated over $350,000 from its 2 storefronts in fiscal year 2019.
Emerald Organic Products - CBD and...
https://www.emerald-organic.com
Emerald Organic Products Hires Ex-Quest Nutrition Executive as Head of Sales
Director of Worldwide Sales at Quest Nutrition
The Simply Good Foods Company (NASDAQ:SMPL) announced that it would acquire Quest Nutrition, LLC for $1 billion USD in cash on expected annual revenue of $345 million.
Pura Vida Vitamins
https://www.puravidavitamins.com/cbd-gummies/
PETV - PetVivo Holdings, Inc.
EMOR entered into an exclusive licensing agreement for the use of OraPatch™, a patented oral delivery method for various substances including caffeine and cannabidiol (“CBD”) from PetVivo Holdings, Inc.
The patented oral adhesion technology, OraPatch™, is a slowly degradable protein wafer-disc that attaches to and assimilates with the mouth’s inner lining. PetVivo is the holder of patents for this unique and cutting-edge method for nutraceutical and supplement delivery.
https://www.emerald-organic.com/press-release...ldings-inc
EMOR 51% stake in Bezalel’s Jewelry, Inc.
vending machine manufacturing and distributing company,
1. These unique vending machines employ facial recognition software and can positively identify people with I.D. from 143 countries worldwide.
“we are particularly excited about the machines presentation, which allows for HD quality advertising offering a significant revenue opportunity”
https://patents.justia.com/assignee/bezalel-s-jewelry-inc
Contract with
https://www.sportandwellnessltd.com
VPs
Wellness Executive VP Sales and Marketing, Chris Mattina
Patrick Kenny, CEO of Sport and Wellness Living.
https://www.traub.io/team/pat-kenny/
Amarantus is receiving an up-front payment of preferred stock in Emerald to be valued at a minimum of $66.6 million (the “Preferred”), and will receive single digit royalties, with a right to buy into up to double-digit royalties until April 2022. The Preferred is convertible into 33,333,333 shares of Emerald common stock in April 2022. Prior to April 2022, Amarantus may convert the Preferred stock to common stock in Emerald upon the common stock trading above $5 on average volume of 1,000,000 shares traded for a period of 20 days
Cutanogen / ESS owns 90.1%
MANF Therapeutics 100%
PhenoGuard
"We now intend to focus on developing these assets through strategic partnerships to unlock their full potential."
TBD - negotiations on-going eith EMOR
Elto Pharma AMBS’ 50.1%-owned
JV partner Psychogenics, Inc.
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease
Patent extends patent coverage for eltoprazine to 2034
The potential for cannabinoid pharmaceuticals is rooted in their potentially synergistic effects with other traditional pharmaceutical compounds, such as eltoprazine. We are very pleased with this first notice of allowance that we’ve received from this international patent family, and we expect to receive many more in the months from jurisdictions around the world, including the United States.”
1st Lab AMBS has direct access to
Todos Medical option to acquire Provista Dx
Provista Diagnostics, Inc., an in vitro diagnostics company with a CLIA/CAP certified lab
Provista Diagnostics has received investments of over $50M which it has used to develop a stable, antibody-based simple blood test that measures the presence of Tumor-associated Auto-Antibodies (TAAbs) and Serum Protein Biomarkers (SRPs)
Todos has exercised its exclusive option to acquire Amarantus’ remaining ownership in Breakthrough in exchange for approximately 49% ownership of Todos.
The transaction is expected to close in the frist half of 2020.
Videssa Breast DX CLIA certified
From the TBIA Platform
TM- B1 - CE Mark granted
TM-B2 - CE Mark granted
In parallel, Todos’ TM-B1 and TM-B2 assays will gain valuable information by piggybacking on Videssa’s patient flow
Also has TM-C1 Colon Cancer CE Mark granted
Orot+ will be responsible for marketing and distribution costs and execution associated with commercializing the breast cancer tests in Romania and Austria. Todos Medical will be able to use the data gathered from these initiatives to support further development and commercialization in other jurisdictions.
We look forward to working with Todos for many years to come
Todos and Orot are currently enrolling patients in a commercial validation study to support the commercial launch of the TM-B1 and TM-B2 blood tests later this year.
Orot+ has agreed to spend a minimum of $2.5M towards clinical development, regulatory approval and commercial launch of the tests by way of a soon to be formed Japanese Distribution Company
Todos & AMBS are working to complete the all-stock acquisition of Amarantus’ subsidiary Breakthrough Diagnostics into Todos Medical in the near future.
Breakthrough Diagnostics - 80.01%-owned by AMBS
LymPro Test ®
MSPrecise™
NuroPro.
Gerald was appointed as CEO of Todos primarily to help Todos implement its plans to bring its blood testing technologies into the US market and list its common stock onto a US national stock exchange, which would ultimately create substantial value for Amarantus
2nd Lab AMBS has access to
Avant Diagnostics, Inc, approx 30% of common
a tumor analysis company developing Theralink®,
Our laboratory is ~95% complete and we have one of our new Ph.D.’s, from George Mason University (“GMU”), on site busily preparing us for our lab opening
I may have missed something, just shows how much Gerald is doing and why Amarantus of new is not Amarantus of past.
Aloha
(4)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼